ctermin
domain
ntermin
domain
interact
influenza
polymeras
modul
assembl
subunit
may
serv
valuabl
target
develop
novel
antiinfluenza
therapeut
studi
perform
systemat
screen
chemic
librari
follow
antivir
evalu
primari
hit
analogu
eventu
novel
smallmolecul
compound
abrog
associ
impair
viral
polymeras
activ
identifi
exhibit
antivir
activ
influenza
viru
subtyp
cell
cultur
partial
protect
mice
lethal
challeng
mouseadapt
influenza
viru
surprisingli
panel
subtyp
influenza
viru
includ
show
variou
degre
resist
compound
biochem
studi
reveal
similar
pattern
resist
impair
polymeras
activ
molecular
dock
analys
suggest
site
appear
complet
conserv
among
subtyp
viru
mention
thu
propos
alternativeaddit
bind
site
may
exist
regul
subunit
assembl
influenza
viru
limit
therapeut
option
influenza
viru
increas
challeng
drugresist
make
endeavor
nextgener
antivir
agent
imper
hayden
de
jong
ison
kelso
hurt
recent
advanc
understand
molecular
mechan
influenza
viru
iav
replic
hint
new
avenu
develop
antivir
agent
target
viral
protein
da
et
al
host
factor
muller
et
al
gener
virustarget
antivir
function
inhibit
biolog
process
viral
protein
mostli
enzymat
activ
altern
may
block
viral
proteinprotein
interact
ppi
essenti
viru
replic
machineri
lou
et
al
hosttarget
antivir
inspect
hostviru
battleground
focu
cellular
factor
involv
viral
life
cycl
host
immun
respons
believ
sophist
strategi
sinc
minim
emerg
drug
resist
watanab
kawaoka
nevertheless
virustarget
antivir
polymeras
proteas
inhibitor
still
major
choic
develop
antivir
therapi
probabl
due
comprehens
understand
underli
mechan
lou
et
al
recent
progress
polymeras
structur
bat
influenza
viru
human
influenza
b
viru
influenza
c
viru
hengrung
et
al
provid
tremend
insight
complex
architectur
rnadepend
rna
polymeras
rdrp
function
viral
rna
synthesi
machin
rdrp
produc
either
crna
vrna
de
novo
replic
viral
mrna
transcript
capsnatch
function
hous
catalyt
site
polymeras
activ
bind
cap
structur
cellular
premrna
cleav
pa
endonucleas
use
primer
viral
mrna
synthesi
eisfeld
et
al
structur
heterotrimer
complex
assembl
intersubunit
interfac
pa
ctermin
domain
pacter
ntermin
domain
et
al
obayashi
et
al
ctermin
domain
ntermin
domain
sugiyama
et
al
undoubtedli
inhibit
pa
endonucleas
yuan
et
al
capbind
yuan
et
al
valid
mean
term
virustarget
antivir
develop
anoth
appeal
strategi
inhibit
rdrp
function
interfer
proper
assembl
use
ppi
inhibitor
end
small
molecul
compound
target
pacter
interplay
activ
pursu
sinc
massari
et
al
murator
et
al
yuan
et
al
intriguingli
antiinfluenza
agent
target
interfac
never
report
yet
perform
elisabas
screen
chemic
librari
kao
et
al
smallmolecul
compound
subsequ
primari
hit
analogu
screen
antivir
potenc
iav
replic
inhibitor
methyliden
design
identifi
lead
compound
select
index
around
proceed
evalu
antivir
efficaci
among
differ
subtyp
iav
surprisingli
result
suggest
strainspecif
antivir
effect
compound
suppress
viru
replic
iav
wherea
less
effect
infect
iav
madindarbi
canin
kidney
mdck
cell
human
embryon
kidney
cell
maintain
describ
previous
yuan
et
al
upon
viru
infect
infect
cell
maintain
fb
free
medium
supplement
without
mgml
tpck
trypsin
total
subtyp
influenza
propag
embryon
hen
egg
use
vivo
antivir
test
experi
live
virus
conduct
use
biosafeti
level
facil
describ
previous
zheng
et
al
test
compound
purchas
chembridg
corpor
san
diego
usa
unless
specifi
peptid
synthes
cellmano
biotech
limit
hefei
china
puriti
fulllength
protein
express
mammalian
cell
express
system
invitrogen
purifi
histag
affin
chromatographi
briefli
cell
line
suspens
cultiv
freestyl
medium
gibco
orbit
shaker
c
incub
humidifi
atmospher
co
mammalian
express
plasmid
gene
transfect
cell
ml
polyethylenimin
pei
transfect
reagent
longo
et
al
transfect
cell
harvest
h
posttransfect
cell
pellet
lyse
iper
protein
extract
reagent
pierc
accord
manufactur
protocol
protein
purifi
solubl
cell
lysat
use
ninta
agaros
qiagen
follow
overnight
dialysi
mm
hepe
ph
protein
concentr
detect
western
blot
use
rabbit
polyclon
antibodi
thermo
fisher
describ
previous
inhibitori
effect
peptid
compound
polymeras
activ
ahong
evalu
use
minireplicon
assay
yuan
et
al
detail
protocol
specifi
supplementari
materi
multicycl
viru
growth
assay
appli
evalu
antivir
activ
chemic
compound
peptid
experiment
procedur
outlin
supplementari
materi
compound
screen
previous
describ
elisa
murator
et
al
modif
briefli
elisa
plate
coat
ngwell
fulllength
protein
c
overnight
block
c
h
wash
increas
amount
probe
ng
per
well
ad
well
incub
c
h
subsequ
intens
wash
carri
follow
addit
streptavidinhrp
invitrogen
tmb
substrat
absorb
read
nm
elisa
plate
reader
tecan
sunris
competit
bind
assay
deriv
short
peptid
fuse
cellpenetr
sequenc
tat
use
posit
control
inhibitor
suppl
tabl
prepar
reaction
seriallydilut
peptid
inhibitor
ng
per
well
coincub
ngwell
probe
ad
well
coat
ngwell
primari
screen
perform
accord
condit
optim
competit
bind
elisa
small
molecul
librari
compound
appli
chemic
librari
collect
primari
hit
show
anticytopath
effect
cpe
influenza
viru
infect
kao
et
al
importantli
screen
artifici
compound
could
interrog
known
target
viral
infect
sar
coronaviru
etc
kao
et
al
brief
individu
compound
mgml
mix
mgml
probe
coincub
plate
coat
ngwell
fulllength
protein
compound
result
decreas
valu
compar
posit
control
ie
select
next
doseerespons
analysi
done
identifi
activ
compound
consist
block
protein
bind
afterward
secondari
screen
perform
plaqu
reduct
assay
evalu
vitro
efficaci
activ
compound
compound
seriallydilut
mm
exhibit
dosedepend
plaqu
reduct
chosen
studi
balbc
femal
mice
week
old
kept
biosafeti
hous
given
access
standard
pellet
feed
water
ad
libitum
experiment
protocol
approv
anim
ethic
committe
univers
hong
kong
refer
number
culatr
perform
complianc
standard
oper
procedur
biosafeti
anim
facil
total
group
micegroup
mice
evalu
anesthesia
mice
intranas
inocul
ml
lethal
dose
mouseadapt
viru
therapeut
treatment
initi
h
postviruschalleng
one
group
mice
intranas
inocul
ml
mg
ml
mgkg
second
group
mice
administ
ml
mgml
zanamivir
mgkg
posit
control
zanamivir
brand
name
relenza
influenza
neuraminidas
inhibitor
commonli
prescrib
prevent
treatment
human
infect
third
group
inocul
pb
untreat
control
two
dose
per
day
zanamivir
pb
administ
day
total
dosesmous
anim
surviv
vital
sign
monitor
day
death
bodi
weight
loss
set
human
endpoint
addit
three
mice
group
euthan
day
postchalleng
mous
lung
collect
viru
titrat
plaqu
assay
rtqpcr
method
yuan
et
al
mous
surviv
rate
two
challeng
dose
ie
mld
detect
regimen
appli
describ
rtqpcr
assay
perform
determin
abund
viral
mrna
crna
vrna
reflect
viral
polymeras
activ
presenc
absenc
method
modifi
previou
report
kawakami
et
al
briefli
differ
subtyp
viru
inocul
mdck
cell
plate
moi
one
hour
viru
inocul
inoculum
remov
cell
maintain
without
mm
postinfect
total
rna
extract
cell
lysat
use
rneasi
mini
kit
qiagen
viral
cdna
synthes
use
taggedprim
np
gene
follow
realtim
pcr
detect
lightcycl
roch
abl
specif
distinguish
quantifi
influenza
vrna
crna
mrna
level
cellular
bactin
mrna
includ
intern
control
relev
primer
list
suppl
tabl
structur
file
bound
peptid
deriv
apuerto
strain
retriev
protein
data
bank
pdb
sugiyama
et
al
cocrystal
peptid
ligand
remov
structur
dock
carri
patchdock
schneidmanduhovni
et
al
protein
structur
consid
rigid
bodi
ligand
fulli
flexibl
one
hundr
dock
solut
comput
interact
paramet
set
default
predict
model
refin
firedock
mashiach
et
al
best
bind
solut
file
visual
valid
schroding
maestro
oding
second
dock
method
igemdock
algorithm
hsu
et
al
appli
confirm
result
detail
patchdock
firedock
outlin
supplementari
materi
hypothes
viral
rna
synthesi
could
block
specif
inhibit
viral
polymeras
complex
format
target
heterooligomer
thu
deriv
short
peptid
may
fulfil
criteria
test
reuther
et
al
facilit
cell
intern
addit
ctermin
amino
acid
ygrkkrrqrrrpp
hiv
transduct
domain
tat
fuse
construct
suppl
tabl
test
whether
disturb
format
rdrp
affect
activ
minireplicon
assay
base
gene
carri
presenc
absenc
fusion
peptid
shown
fig
addit
result
dosedepend
inhibit
report
gene
activ
wherea
neglig
cytotox
detect
result
suggest
abl
enter
cell
impair
polymeras
activ
block
interact
investig
whether
could
suppress
viru
replic
viru
titer
supernat
detect
scrambledtat
peptid
consist
amino
acid
composit
random
sequenc
includ
neg
control
shown
fig
treatment
caus
small
reduct
viru
titer
compar
scrambledtat
p
mm
concentr
p
mm
concentr
taken
togeth
result
demonstr
fusion
peptid
restrain
influenza
viru
replic
impair
polymeras
activ
thu
bind
site
could
serv
druggabl
target
develop
novel
antiinfluenza
therapeut
compar
antivir
peptid
small
molecul
compound
advantag
better
bioavail
vivo
especi
term
intracellular
target
interfac
leeson
springthorp
intend
identifi
compound
abl
displac
bind
peptid
protein
dissoci
bind
thu
decreas
polymeras
activ
end
elisabas
assay
modifi
screen
kind
compound
use
histag
protein
receptor
biotinyl
peptid
suppl
tabl
probe
surprisingli
bind
domain
properli
exhibit
narrow
dynam
rang
make
target
protein
unsuit
drug
screen
suppl
fig
address
issu
fulllength
protein
appli
shown
fig
plate
coat
fulllength
addit
increas
amount
result
greater
absorb
concentr
protein
probe
maintain
ngwell
ng
well
respect
molar
ratio
addit
peptid
posit
control
exhibit
dosedepend
reduct
absorb
fig
collect
result
demonstr
specif
bind
protein
peptid
suggest
elisa
abl
provid
broad
dynam
rang
screen
bind
inhibitor
result
also
suggest
conform
structur
critic
bind
compound
librari
first
screen
fix
concentr
mgml
elisa
compound
result
decreas
bind
intens
compar
mg
ml
peptid
inhibitor
proceed
carri
doserespons
analysi
identifi
compound
consist
block
protein
probe
bind
accord
result
five
among
compound
defin
activ
ic
mg
ml
data
shown
next
cellbas
plaqu
reduct
assay
appli
identifi
antivir
candid
within
activ
compound
one
compound
name
reduc
plaqu
number
concentrationdepend
manner
regard
antivir
effect
compound
base
structur
properti
twelv
structur
similar
analogu
druglik
properti
lipinski
purchas
appli
structureact
analys
suppl
excel
file
initi
analogu
evalu
inhibitori
effect
bind
follow
plaqu
assay
determin
antivir
potenc
result
show
exhibit
inhibit
bind
viru
replic
structur
two
chlorin
atom
benzen
ring
essenti
maintain
inhibit
suppl
excel
file
select
index
si
ie
ratio
cytotox
concentr
cc
half
maxim
effect
concentr
ec
determin
compar
fig
due
consider
higher
si
select
evalu
antivir
activ
vitro
vivo
evalu
antivir
efficaci
cell
cultur
multicycl
viru
growth
assay
conduct
h
postinfect
pi
compound
display
dramat
antia
effect
reduct
viral
titer
supernat
fig
assess
antivir
effect
vivo
mice
challeng
either
mld
fig
mld
fig
mouseadapt
viru
treat
zanamivir
posit
control
pb
nontreat
control
shown
fig
zanamivirtr
group
show
protect
surviv
rate
group
mice
challeng
mld
viru
upon
lower
challeng
dose
mice
receiv
intranas
treatment
surviv
mice
die
pbstreat
group
fig
surviv
rate
zanamivir
group
fig
result
show
signific
improv
mous
surviv
treatment
p
zanamivir
p
fig
c
mice
infect
mld
challeng
dose
result
demonstr
group
exhibit
reduct
viral
load
p
lung
tissu
compar
pbstreat
control
group
fig
thu
conclud
abl
provid
protect
infect
influenza
viru
vitro
mouseadapt
vivo
sinc
amino
acid
among
iav
interact
region
highli
conserv
fig
assum
might
inhibitori
effect
peptid
viral
polymeras
activ
left
yaxi
test
minireplicon
assay
cytotox
cell
right
yaxi
determin
mtt
assay
minireplicon
assay
indic
concentr
ad
h
posttransfect
luminesc
fluoresc
determin
h
posttransfect
respect
mtt
assay
variou
concentr
incub
cell
h
addit
mtt
substrat
experi
carri
triplic
repeat
twice
data
present
mean
valu
sd
b
antivir
effect
evalu
mdck
cell
use
multicycl
viru
growth
assay
cell
infect
influenza
viru
moi
viru
intern
inoculum
remov
wash
replac
cultur
medium
contain
peptid
indic
concentr
scrambl
tatpeptid
includ
neg
control
viru
titer
cell
supernat
collect
h
postinfect
determin
plaqu
assay
result
present
mean
valu
sd
two
independ
experi
p
p
compar
scrambledtattr
group
unpair
ttest
virus
inhibit
dosedepend
manner
fig
nevertheless
treatment
unabl
significantli
inhibit
influenza
virus
use
high
mm
determin
rapid
replic
kinet
outpac
effect
antivir
effect
earlier
time
point
evalu
vivo
antivir
efficaci
measur
lethal
mous
model
mice
per
group
infect
mld
mouseadapt
viru
treat
ml
mgml
mgml
zanamivir
pb
intranas
administr
treatment
start
h
viru
challeng
continu
dose
day
dosesday
condit
mice
monitor
day
till
death
c
treatment
regimen
appli
mous
group
challeng
mld
mouseadapt
viru
shown
surviv
curv
b
c
differ
group
compar
analyz
use
logrank
mantelcox
test
indic
p
indic
p
compar
pbstreat
group
mice
infect
mld
mouseadapt
viru
three
mice
group
euthan
day
postinfect
lung
collect
detect
viral
load
plaqu
assay
rtqpcr
result
present
mean
valu
sd
differ
group
compar
use
unpair
ttest
indic
p
indic
p
compar
pbstreat
group
infecti
viru
undetect
zanamivirtr
mous
lung
use
plaqu
assay
result
show
neither
h
h
postinfect
could
suppress
viru
replic
data
shown
taken
togeth
result
reveal
strainsubtypespecif
inhibit
iav
replic
order
explor
variou
degre
sensit
look
viral
polymeras
activ
compar
viru
rna
synthesi
level
shown
fig
mrna
crna
vrna
level
quantifi
infecti
context
present
ratio
mocktreat
sampl
presenc
signific
decreas
mrna
synthes
detect
p
p
p
virusinfect
cell
fig
wherea
signific
differ
observ
cell
infect
virus
p
fig
term
crna
vrna
synthesi
activ
viral
strain
show
reduc
yield
presenc
howev
exhibit
signific
substanti
drop
compar
subtyp
fig
fig
exampl
p
valu
less
subtyp
equal
wherea
p
valu
subtyp
higher
former
three
thu
result
compat
strain
subtypespecif
antivir
effect
suggest
vari
sensit
correl
level
impair
viral
polymeras
activ
elucid
mechan
underli
strainspecif
sensit
align
sequenc
residu
viru
strain
first
look
key
residu
determin
interfac
leu
phe
val
val
ala
ile
ile
sugiyama
et
al
result
show
residu
except
val
fulli
conserv
viru
strain
asterisk
mark
fig
howev
substitut
detect
insensit
viru
strain
eg
contribut
amino
acid
substitut
strainspecif
sensit
might
exclud
next
residu
substitut
posit
found
none
serv
marker
distinguish
resist
strain
subsequ
perform
molecular
dock
analys
predict
potenti
bind
site
bound
sinc
screen
bind
competitor
compound
dock
domain
directli
predict
fig
c
signific
salt
bridg
form
contact
hydroxyl
ser
arg
ile
domain
ethoxyphenyl
arg
arg
two
chlorin
atom
interact
amino
acid
arg
pro
val
intriguingli
residu
complet
conserv
among
viru
strain
test
green
box
postinfect
use
specif
primer
viral
mrna
crna
vrna
product
rna
type
separ
assess
rtqpcr
method
result
shown
ratio
mocktreat
sampl
p
valu
calcul
unpair
ttest
data
present
mean
sd
two
independ
experi
fig
suggest
bind
site
could
account
differenti
sensit
multipl
line
evid
demonstr
interact
valuabl
proteinprotein
interact
target
develop
novel
antiinfluenza
therapeut
sugiyama
et
al
previou
attempt
use
short
peptid
inhibitor
deriv
domain
ie
interfer
interact
fail
ghanem
et
al
side
interact
studi
reveal
peptid
impair
influenza
polymeras
activ
suppress
viru
replic
fig
result
line
anoth
studi
use
gfp
fusion
construct
gfp
dissoci
complex
reuther
et
al
mutagenesi
studi
sugiyama
colleagu
conclud
even
singl
substitut
interfac
could
inhibit
rna
synthesi
sugiyama
et
al
indic
interact
surfac
small
opportun
develop
small
molecul
ppi
inhibitor
feasibl
verifi
postul
experiment
competit
elisa
util
fig
enabl
initi
identif
antiinfluenza
effect
compound
fig
notabl
one
effect
compound
shown
provid
protect
infect
influenza
vitro
mouseadapt
vivo
fig
exhibit
modest
vivo
antiinfluenza
activ
compar
commerci
avail
drug
zanamivir
fig
limit
moder
bioavail
vivo
hand
worth
note
intranas
treatment
use
studi
may
facilit
influenza
viru
infect
promot
lung
patholog
smee
et
al
appar
drug
deliveri
intranas
rout
direct
effici
howev
intranas
liquid
also
help
spread
viru
insid
mous
lung
taylor
therefor
treatment
influenza
viru
infect
intranas
rout
requir
addit
optim
viru
challeng
dose
avoid
compromis
effect
potenti
use
antivir
agent
novel
artifici
synthes
compound
whose
biolog
test
result
never
mention
howev
surpris
inhibit
viru
replic
strainsubtypespecif
even
though
drug
target
highli
conserv
among
variou
subtyp
fig
observ
agreement
report
reuther
et
al
conclud
differ
assembl
strategi
influenza
polymeras
util
gfp
fusion
protein
target
interfac
reuther
et
al
investig
reason
differenti
inhibit
examin
sensit
iav
rdrp
found
polymeras
activ
viru
strain
less
impair
fig
rdrp
influenza
viru
serv
hub
viral
transcript
replic
tradit
influenza
polymeras
activ
evalu
fig
sequenc
align
molecular
dock
analys
sequenc
align
ctermin
fragment
residu
influenza
viru
strain
shown
residu
red
ident
viru
strain
substitut
blue
purpl
predict
bind
site
highlight
green
box
shown
complet
conserv
interfac
residu
conclud
previou
crystal
structur
label
asterisk
align
done
vector
nti
life
technolog
b
twodimension
dock
analysi
c
ribbon
diagram
interact
shown
two
chlorin
atom
contact
amino
acid
arg
pro
val
remain
chemic
group
interact
residu
ser
arg
arg
ile
arg
structur
analysi
chemic
structur
shown
stick
model
wherea
interact
amino
acid
residu
label
black
interpret
refer
colour
figur
legend
reader
refer
web
version
articl
minireplicon
assay
fig
howev
clone
work
becom
tediou
scenario
measur
polymeras
activ
sever
viru
strain
find
altern
rtqpcr
method
util
fig
determin
specif
assay
minireplicon
assay
base
viral
gene
carri
shown
suppl
fig
polymeras
activ
exhibit
dosedepend
greater
sensit
inhibit
group
valid
role
rtqpcr
method
altern
minireplicon
assay
importantli
assay
abl
quantifi
mrna
crna
vrna
synthesi
activ
across
differ
viru
subtyp
iav
took
account
context
infecti
event
instead
recombin
enzym
complex
thu
may
better
recapitul
key
physiolog
aspect
polymeras
activ
elucid
discrep
observ
differ
influenza
subtyp
first
specul
structur
variat
differ
domain
might
play
role
thu
sequenc
align
focus
interact
residu
well
predict
site
carri
fig
furthermor
dock
simul
base
either
isol
complex
fig
c
whole
architectur
influenza
polymeras
heterotrim
suppl
fig
carri
result
suggest
interact
similar
fulli
ident
residu
whose
differ
might
due
structur
batspecif
influenza
polymeras
differ
humanavian
strain
ii
conform
chang
assembl
polymeras
heterotrim
deng
et
al
howev
analys
suggest
none
mention
residu
could
account
variou
degre
sensit
furthermor
shown
effect
fig
exert
similar
specif
antivir
efficaci
suppl
fig
investig
whether
substitut
could
caus
differ
suscept
align
test
virus
carri
one
substitut
posit
ie
identifi
suppl
fig
howev
role
strainspecif
inhibit
iav
exclud
previou
report
reuther
et
al
taken
togeth
specul
either
molecular
dock
essenti
identifi
bind
site
limit
sole
avail
unident
structur
dock
simul
altern
addit
bind
locat
beyond
one
investig
studi
might
exist
mediat
associ
even
though
theoret
bind
conserv
region
across
differ
subtyp
consequ
altern
interact
site
would
abl
sustain
assembl
polymeras
complex
vn
hk
even
contact
function
block
one
previou
map
analys
function
domain
influenza
subunit
reveal
ctermin
domain
residu
exhibit
bind
activ
toward
subunit
pool
et
al
verifi
altern
bind
site
locat
detect
interact
subunit
domain
use
coimmunoprecipit
analysi
elisa
tool
howev
result
show
fail
associ
fulllength
experi
data
shown
suggest
suppos
bind
site
locat
region
anoth
hypothesi
propos
ntermin
domain
pa
protein
panter
act
molecular
mediat
interplay
caus
fact
dimer
instead
monom
contact
deng
et
al
reuther
et
al
thu
possibl
conform
chang
induc
upon
bind
consequ
case
dimer
influenza
viru
might
shield
bind
site
contact
altern
manner
verifi
howev
indepth
analys
identifi
decis
amino
acid
panter
distinguish
sensit
viru
strain
shall
carri
futur
studi
overal
effort
demonstr
possibl
suppress
viral
replic
abrog
bind
confirm
antivir
activ
deriv
peptid
addit
perform
systemat
screen
chemic
librari
identifi
novel
smallmolecul
compound
antivir
activ
influenza
viru
includ
subtyp
howev
strainsubtyp
specif
antivir
properti
also
suggest
altern
bindingmedi
site
interfac
may
contribut
associ
